IGF signaling is known to be activated in about 80–90% of cases (49, 50) and the IGFR/IR inhibitor linsitinib has been demonstrated to be a promising targeted therapy for ACC by in vitro experiments (33). This evidence concerns the gene IGF1R and adrenal cortex carcinoma.